Experimental iron deficiency drug meets primary endpoint

09/4/2013 | Reuters

Data from the second of two late-stage trials showed Rockwell Medical's experimental iron deficiency drug Soluble Ferric Pyrophosphate helped improve hemoglobin levels in adult chronic kidney disease patients on hemodialysis. The drug is administered through the fluid used in dialysis and would replace the standard intravenous iron treatment in patients.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations